Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.12. | HSI Closes at 20,155, Down 156 pts; HSTI Closes at 4,531, Down 60 pts; HANG LUNG PPT Down over 3%; FOSUN TOURISM, CARSGEN-B, MOBVISTA, SY HOLDINGS, MARKETINGFORCE Hit New Highs; Market Turnover Rises | 7 | AASTOCKS | ||
10.12. | CARSGEN-B (02171): TERMS OF REFERENCE FOR THE AUDIT COMMITTEE | 2 | HKEx | ||
10.12. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON ZEVOR-CEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS | 1 | HKEx | ||
18.11. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME | - | HKEx | ||
01.11. | CARsgen Therapeutics: CARsgen U.S. Clinical Holds Lifted by FDA | 54 | PR Newswire | SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for... ► Artikel lesen | |
01.11. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - LIFT OF THE U.S. CLINICAL HOLDS FOR ZEVORCABTAGENE AUTOLEUCEL, SATRICABTAGENE AUTOLEUCEL AND CT071 BY FDA | 1 | HKEx | ||
17.10. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - TO PRESENT ZEVORCABTAGENE AUTOLEUCEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS | 1 | HKEx | ||
CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
10.10. | China's CARsgen Applies to Resume CAR-T Cell Therapy Trials in US After Passing Reinspection | 1 | Yicai Global | ||
09.10. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - APPLICATION TO REQUEST LIFTING CLINICAL HOLDS SUBMITTED TO FDA | 1 | HKEx | ||
09.09. | CARSGEN-B (02171): INTERIM REPORT 2024 | 1 | HKEx | ||
29.08. | CARsgen Therapeutics: CARsgen Announces 2024 Interim Results | 119 | PR Newswire | SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies... ► Artikel lesen | |
28.08. | CARSGEN-B (02171): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
19.08. | CARsgen Therapeutics: CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel) | 89 | PR Newswire | SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies... ► Artikel lesen | |
19.08. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF CONFIRMATORY PHASE II CLINICAL TRIAL OF SATRICABTAGENE AUTOLEUCEL IN CHINA | 1 | HKEx | ||
15.08. | CARSGEN-B (02171): DATE OF BOARD MEETING | 1 | HKEx | ||
28.06. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
27.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER AND SHARE REPURCHASE BY THE COMPANY | 1 | HKEx | ||
15.06. | CARsgen Therapeutics: CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 | 474 | PR Newswire | SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies... ► Artikel lesen | |
29.04. | CARsgen Therapeutics: CARsgen Submitted Responses to FDA Observations | 93 | PR Newswire | SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies... ► Artikel lesen | |
27.03. | CARsgen Therapeutics: CARsgen Announced 2023 Annual Results | 181 | PR Newswire | SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
QIAGEN | 42,900 | +0,04 % | Biotech Report: Evotec klettern, Qiagen leichter | (shareribs.com) Frankfurt / New York 16.12.2024 - Die Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Für Evotec ging es nach oben, während Qiagen und auch Biontech korrigierten. An der... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
EVOTEC | 8,405 | +1,08 % | Evotec-Aktie: Geht es jetzt weiter bergab - oder kommt doch noch in Kürze der große Durchbruch? Wir analysieren und verraten Ihnen unsere Tradingidee! | © Foto: SymbolbildWas passiert mit Evotec? Die Aktie des Hamburger Biotech-Unternehmens hatte 2024 kein einfaches Jahr: Fast 60 Prozent Kursverlust, Gerüchte über eine Übernahme und die Rückkehr in... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |